Scott Hofsess

447 total citations · 1 hit paper
5 papers, 149 citations indexed

About

Scott Hofsess is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Scott Hofsess has authored 5 papers receiving a total of 149 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Scott Hofsess's work include HER2/EGFR in Cancer Research (4 papers), Cancer therapeutics and mechanisms (2 papers) and Advanced Breast Cancer Therapies (2 papers). Scott Hofsess is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Cancer therapeutics and mechanisms (2 papers) and Advanced Breast Cancer Therapies (2 papers). Scott Hofsess collaborates with scholars based in United States, Belgium and Spain. Scott Hofsess's co-authors include Thomas M. Cardillo, Greg M. Thurber, Serengulam V. Govindan, Véronique Dièras, Kevin Kalinsky, Oh Kyu Yoon, Kevin Punie, Javier Cortés, Luca Gianni and Sara M. Tolaney and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Molecular Cancer Therapeutics.

In The Last Decade

Scott Hofsess

5 papers receiving 146 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

2024 71 citations Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott Hofsess United States	4	125	61	46	28	21	5	149
Agnès Ducoulombier France	6	113 0.9×	56 0.9×	59 1.3×	15 0.5×	22 1.0×	14	138
Jeannette Dinin United States	2	93 0.7×	49 0.8×	26 0.6×	34 1.2×	13 0.6×	2	128
Eva Schumacher-Wulf Germany	5	113 0.9×	37 0.6×	83 1.8×	15 0.5×	18 0.9×	14	142
Hannah Dzimitrowicz United States	5	103 0.8×	31 0.5×	47 1.0×	29 1.0×	47 2.2×	12	150
Wenqin Feng United States	5	124 1.0×	48 0.8×	75 1.6×	30 1.1×	23 1.1×	9	149
Klaus Kirchbacher Austria	5	48 0.4×	21 0.3×	51 1.1×	35 1.3×	30 1.4×	10	104
Francesca Pettinella United States	4	75 0.6×	51 0.8×	19 0.4×	29 1.0×	6 0.3×	8	122
Kaline Pereira Japan	4	129 1.0×	42 0.7×	102 2.2×	16 0.6×	21 1.0×	8	152
Kathleen Harnden United States	7	74 0.6×	24 0.4×	62 1.3×	25 0.9×	37 1.8×	15	144
Elizabeth E. Ravenberg United States	5	63 0.5×	33 0.5×	45 1.0×	9 0.3×	45 2.1×	11	99

Countries citing papers authored by Scott Hofsess

Since Specialization

Citations

This map shows the geographic impact of Scott Hofsess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Hofsess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Hofsess more than expected).

Fields of papers citing papers by Scott Hofsess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Hofsess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Hofsess. The network helps show where Scott Hofsess may publish in the future.

Co-authorship network of co-authors of Scott Hofsess

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Hofsess. A scholar is included among the top collaborators of Scott Hofsess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Hofsess. Scott Hofsess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Bardia, Aditya, Hope S. Rugo, Sara M. Tolaney, et al.. (2024). Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of Clinical Oncology. 42(15). 1738–1744. 71 indexed citations breakdown →

2.

Nair, Jayakumar R., Tzu‐Ting Huang, Ken Cheng, et al.. (2024). Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer. iScience. 27(12). 111283–111283. 2 indexed citations

3.

Nessler, Ian, et al.. (2023). Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo. Molecular Cancer Therapeutics. 23(3). 343–353. 6 indexed citations

4.

Hofsess, Scott, et al.. (2022). Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release. Molecular Cancer Therapeutics. 22(1). 102–111. 52 indexed citations

5.

Hurvitz, SA, Amit Bardia, Kevin Punie, et al.. (2022). 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study. Annals of Oncology. 33. S200–S201. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact